Connect with us

Alzheimer’s Disease

Commission authorises medicine for treatment of early Alzheimer's disease

SHARE:

Published

1 month ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

The Commission has granted EU authorization for Leqembi, a medicine to treat mild cognitive impairment in the early stages of Alzheimer's disease, under strict conditions. It is the first such medicine to be authorized in the EU.

This medicine is for use in people who have only one or no copy of the ApoE4 gene and who have amyloid beta plaques in the brain. 

The authorisation is based on the positive scientific assessment of the European Medicines Agency, which concluded that the benefits of this medicine outweighed the risks, in a particular population of patients with such disease and as long as risk minimisation measures are applied. Therefore, the authorisation decision also sets strict conditions on the use of Leqembi, as well as clear risk mitigation requirements.

Share this article:

Related Topics:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending